The Hypertrans® technology enables plants to express a wide variety of proteins of potential commercial value.
The high-speed technology means vaccines can be tailored rapidly and accurately to specific threats as they emerge. Production of vaccines with this technology does not require costly high-containment facilities.
The patented technology has been licensed to Canadian company Medicago for production of vaccines for the global market. Leaf Expression Systems will use the technology for the commercialisation of a range of human and animal vaccines, and the biotherapeutic and high-value proteins markets.
The technology has also been licensed to UK start-up Leaf Expression Systems, a joint venture between ourselves, BBSRC and Plant Biosciences Ltd, on the Norwich Research Park.